SCHEMBL15920693

SCHEMBL15920693

COC(=O)c1ccc(C(=O)CBr)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.51
ALDH1A1 P00352 8/20 0.51
MAPT P10636 5/20 0.51
HSD17B10 Q99714 4/20 0.51
HPGD P15428 3/20 0.51
GAA P10253 2/20 0.51
GLA P06280 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
ATM Q13315 1/20 0.51
LMNA P02545 2/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
XDH P47989 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GSK3B P49841 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15544448 0.89 ALDH1A1 (0.49) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL28547135 0.87 GSK3B (0.50) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL7920331 0.84 KDM4E (0.49) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL45823 0.82 KDM4E (0.67) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL11901698 0.82 KDM4E (0.50) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL5335630 0.82 CA12 (0.59) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL31386371 0.81 PDGFRB (0.43) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL28125731 0.81 GSK3B (0.50) MAPTGSK3BKMT2AHPGDS
SCHEMBL15544203 0.81 ALDH1A1 (0.46) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL30985101 0.81 MAPT (0.54) KDM4EALDH1A1MAPTHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727591-A1 SMARCA2 DEGRADERS AND USES THEREOF Astrazeneca AB (SE) 2026-04-22 EP disclosed
WO-2024256988-A1 SMARCA2 DEGRADERS AND USES THEREOF ASTRAZENECA AB (SE) 2024-12-19 WO disclosed
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2023-12-21 US disclosed
EP-3998267-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Bellus Health Cough Inc. (CA) 2022-05-18 EP disclosed
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2022-03-03 US disclosed
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2022-03-03 US disclosed
EP-3381917-B1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF BELLUS HEALTH COUGH INC (CA) 2021-09-08 EP disclosed
EP-3381917-B1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF BELLUS HEALTH COUGH INC (CA) 2021-09-08 EP disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 US disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 US disclosed
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2017-05-25 US disclosed
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2017-05-25 US disclosed
US-9598409-B2 Imidazopyridine compounds and uses thereof NEOMED INSTITUTE (CA) 2017-03-21 US disclosed
US-9598409-B2 Imidazopyridine compounds and uses thereof NEOMED INSTITUTE (CA) 2017-03-21 US disclosed
US-9598409-B2 Imidazopyridine compounds and uses thereof NEOMED INSTITUTE (CA) 2017-03-21 US disclosed
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2015-12-17 US disclosed
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2015-12-17 US disclosed
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2015-12-17 US disclosed
EP-2951177-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Neomed Institute (CA) 2015-12-09 EP disclosed
WO-2014117274-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NEOMED INSTITUTE (CA) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS KDM4E 1264/4885ALDH1A1 664/4885MAPT 2247/4885
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof NISCH, ABL1, PAICS KDM4E 1264/4885ALDH1A1 664/4885MAPT 2247/4885
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS KDM4E 1264/4885ALDH1A1 664/4885MAPT 2247/4885
US-20170143730-A1 Imidazopyridine Compounds and Uses Thereof NISCH, ABL1, PAICS KDM4E 1264/4885ALDH1A1 664/4885MAPT 2247/4885
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS KDM4E 1264/4885ALDH1A1 664/4885MAPT 2247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.